The clinical effectiveness agency for England and Wales has issued draft guidance opposing use of pemetrexed as a maintenance treatment for people with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.Pemetrexed was approved by the National Institute for Health and Clinical Excellence in September as a first-line treatment option for non-small-cell lung cancers, yet its manufacturer's conclusions as to its cost-effectiveness as a maintenance...